To evaluate short-term choroidal thickness changes following intravitreal dexamethasone implant (DEX), ranibizumab (RAN), and triamcinolone acetonide (TA) in eyes with retinal vein occlusion (RVO) and macular edema (ME).
Methods
In this prospective study, 35 eyes of 35 patients with RVO and ME who were treated with intravitreal injections of DEX, RAN, and TA were included. Choroidal thickness was measured using semiautomated segmentation of enhanced depth imaging with optical coherence tomography at fovea and parafoveal areas. Changes in choroidal thickness following treatment were compared statistically.
Results
Choroidal thickness decreased following DEX, RAN, and TA treatments (all p>0.05). In the DEX group, at the first month nasal 1,500 µm (N11,500) and at the third month subfoveal (SF3) and nasal 500 µm (N3500) choroidal thickness revealed a significant reduction compared to RAN and TA groups (all p<0.05). In the TA group, choroidal thickness showed a significant reduction only at nasal 1,500 µm (N31,500) at the third month (p<0.05).
Conclusions
Choroidal thickness was decreased in all 3 groups. The DEX and TA groups showed a significant reduction at some areas. Ranibizumab had the smallest effect on choroidal thickness after 3 months among all groups.
LukschAMaárNTittlMEvaluation of pulsatile choroidal blood flow in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):548–550
2.
ShinYULeeMJLeeBRChoroidal maps in different types of macular edema in branch retinal vein occlusion using swept-source optical coherence tomography. Am J Ophthalmol. 2015;160(2) 328–334
3.
KimKHLeeDHLeeJJParkSWByonISLeeJERegional choroidal thickness changes in branch retinal vein occlusion with macular edema. Ophthalmologica. 2015;234(2):109–118
4.
NittaFKunikataHAizawaNThe effect of intravitreal bevacizumab on ocular blood flow in diabetic retinopathy and branch retinal vein occlusion as measured by laser speckle flowgraphy. Clin Ophthalmol. 2014;8:1119–1127
5.
KimMLeeDHByeonSHKohHJKimSSLeeSCComparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion. Br J Ophthalmol. 2015;99(9):1271–1276
6.
Group TBVOS; The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271–282
7.
BrownDMCampochiaroPASinghRPet al;CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–1133
8.
HallerJABandelloFBelfortRJret al;OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146
9.
HallerJABandelloFBelfortRJret al;Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453–2460
10.
AdamisAPMillerJWBernalMTIncreased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445–450
11.
KanedaSMiyazakiDSasakiSMultivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci. 2011;52(6):2982–2988
12.
Ki-IYArimuraNNodaYStromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion. Curr Eye Res. 2007;32(12):1065–1072
13.
NomaHFunatsuHHarinoSMimuraTEguchiSHoriSVitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol. 2011;55(3):248–255
14.
NomaHFunatsuHMimuraTShimadaKIncrease of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study. J Inflamm. 2010;7:44
15.
OkunukiYUsuiYKataiNRelation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol. 2011;151(4):610–616
16.
NabihMPeymanGATawakolMENaguibKToxicity of high-dose intravitreal dexamethasone. Int Ophthalmol. 1991;15(4):233–235
17.
GewailyDGreenbergPBIntravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2009;1:CD007324
18.
MayerWJWolfAKerntMTwelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye. 2013;27(7):816–822
19.
LeeEKHanJMHyonJYYuHGChanges in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion. Br J Ophthalmol Epub 2015 Apr 16.
20.
CampochiaroPAHeierJSFeinerLet al;BRVAO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102–1112
21.
BrownDMCampochiaroPASinghRPet al;CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–1133
22.
BrownDMCampochiaroPABhisitkulRBSustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594–1602
23.
HernándezCCandell-RieraJCiudinAFranciscoGAguadé-BruixSSimóRPrevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects. Cardiovasc Diabetol. 2011;109
24.
RayessNRahımyEYıngGSBaseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol. 2015;159(1):85–91
25.
YiuGManjunathVChiuSJFarsiuSMahmoudTHEffect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. Am J Ophthalmol. 2014; 158(4):745–751
26.
SonodaSSakamotoTYamashitaTEffect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2014;55(6):3979–3985
27.
LaínsIFigueiraJSantosARChoroidal thickness in diabetic retinopathy: the influence of antiangiogenic therapy. Retina. 2014;34(6):1199–1207
28.
SizmazSKucukerdonmezCKalAPinarciEYCananHYilmazGRetinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab. Eur J Ophthalmol. 2014; 24(6):904–910
29.
NauckMKarakiulakisGPerruchoudAPPapakonstantinouERothMCorticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;3412-3309–315
30.
GuthoffRMeigenTHennemannKSchraderWComparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica. 2010;224(5):319–324
31.
HuYJIntravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye. 2010;24(8):1414–1415
32.
ShroffDBhargavaASharmaBGuptaCShroffCCombined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248(8):1203
33.
NodaYOgawaAToyamaTUetaTLong-term increase in subfoveal choroidal thickness after surgery for senile cataracts. Am J Ophthalmol. 2014;158(3):455–459
34.
XuJXuLDuKFSubfoveal choroidal thickness in diabetes and diabetic retinopathy. Ophthalmology. 2013;120(10) 2023–2028
35.
ThachABYauLHoangCTuomiLTime to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014;121(5):1059–1066
